论文部分内容阅读
本文报告了对119例未经治疗但经组织学证实为小细胞肺癌的患者,联合化疗在开始前做骨扫描,并在治疗后3、6、12个月重复骨扫描。分析其对小细胞肺癌分期以及存活率的关系。并讨论在化疗中用骨扫描追踪的意义。全组病例根据检查结果,将肿瘤局限在一侧胸腔、纵隔和肺门淋巴结,伴有或无单侧锁骨上淋巴结受累者定为“局限期”,其余均定为“广泛期”。全部患者均用联合化疗,部分合并放疗。治疗中1.5、3、6个月分别重新分期,以评价疗效。治疗前骨扫描:70例(-),49例(+)。其中25例有1—2个异常区,24例为3个以上异常区。119例
This paper reports on 119 untreated patients with histologically proven small-cell lung cancer who underwent bone scans before starting the combination and repeated bone scans 3, 6 and 12 months after treatment. The relationship between the staging and survival rate of small cell lung cancer was analyzed. And discuss the significance of bone scan tracking in chemotherapy. According to the results of the tests, the entire group of patients was confined to one side of the chest, mediastinum and hilar lymph nodes, with or without unilateral supraclavicular lymph node involvement was defined as a “limitation period”, the rest are defined as “widely staged.” All patients were treated with combination chemotherapy, some with radiotherapy. Treatments were rephased at 1.5, 3, and 6 months to assess efficacy. Bone scan before treatment: 70 cases (-), 49 cases (+). Of these, 25 cases had 1-2 abnormal areas and 24 cases had more than 3 abnormal areas. 119 cases